As reported on Fierce BioTech, Roche has discontinued development of its investigational T-cell engager (TCE) RG6382 for systemic lupus erythematosus (SLE), following an internal review that concluded the candidate lacked…
As reported on PharmaBiz, Alebund Pharmaceuticals has announced the first patient has been enrolled and treated in a global Phase IIb clinical trial evaluating AP306, an investigational therapy for hyperphosphatemia…
If you or a loved one has ever survived a stroke, you know that the hardest part of the journey often begins after you leave the hospital. Emergency room doctors…
As reported on Inside Precision Medicine, for years, a chronic spinal cord injury (SCI) has felt like a permanent biological roadblock. When the spinal cord is damaged, the immediate aftermath—known…
As reported on PharmaBiz, AtaiBeckley has announced a key milestone in the development of its investigational depression therapy, VLS-01, with the final participant now dosed in the company’s Phase 2b…
Editor's Note: Patient Worthy is honored to share this story, originally written by Anne and Jerry van Wyk, and shared with us by our friends at the Brighter Hope Foundation.…
As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study…
As reported on Tech Times, Sanofi has reported positive results from its Phase 3 Baby-COMET study evaluating Nexviazyme (avalglucosidase alfa) in infants with infantile-onset Pompe disease (IOPD), one of the…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
